84 related articles for article (PubMed ID: 2956375)
1. A new approach to the identification of pathogenetic factors and to therapy in human primary hypertension.
Korner PI; Jennings GL; Esler MD; Broughton A
J Clin Hypertens; 1987 Jun; 3(2):187-96. PubMed ID: 2956375
[TBL] [Abstract][Full Text] [Related]
2. Pathogenesis of human primary hypertension: a new approach to the identification of causal factors and to therapy.
Korner PI; Jennings GL; Esler MD
J Hypertens Suppl; 1986 Oct; 4(3):S149-53. PubMed ID: 2878068
[TBL] [Abstract][Full Text] [Related]
3. Significance of cardiovascular hypertrophy in the development and maintenance of hypertension.
Korner PI; Bobik A; Jennings GL; Angus JA; Anderson WP
J Cardiovasc Pharmacol; 1991; 17 Suppl 2():S25-32. PubMed ID: 1715480
[TBL] [Abstract][Full Text] [Related]
4. Are cardiac and vascular "amplifiers" both necessary for the development of hypertension?
Korner PI; Bobik A; Angus JJ
Kidney Int Suppl; 1992 Jun; 37():S38-44. PubMed ID: 1385838
[TBL] [Abstract][Full Text] [Related]
5. [Arterial hypertension and dyslipidemia in patients with chronic kidney disease (CKD). Anti-platelet aggregation. Goal oriented treatment].
Cases Amenós A; Goicoechea Diezhandiño M; de Alvaro Moreno F
Nefrologia; 2008; 28 Suppl 3():39-48. PubMed ID: 19018737
[TBL] [Abstract][Full Text] [Related]
6. [Coronary flow in experimental cardiac hypertrophy caused by arterial hypertension].
Wicker P; Tarazi R; Dallocchio M; Bricaud H
Arch Mal Coeur Vaiss; 1982 Jun; 75 Spec No():133-6. PubMed ID: 6214231
[TBL] [Abstract][Full Text] [Related]
7. Regression of cardiac hypertrophy with drug treatment in spontaneously hypertensive rats.
Ruskoaho H
Med Biol; 1984; 62(5):263-76. PubMed ID: 6152298
[TBL] [Abstract][Full Text] [Related]
8. [An evaluation of the therapeutic trials aimed at regression of ventricular hypertrophy in arterial hypertension].
Clémenty J; Dulhoste MN; Bordier P; Lartigue MC; Pons N
Ann Cardiol Angeiol (Paris); 1991 Oct; 40(8):503-8. PubMed ID: 1836942
[TBL] [Abstract][Full Text] [Related]
9. Effect of antihypertensive therapy on the cardiovascular amplifiers.
Korner PI; Adams MA; Jennings GL; Bobik A
Clin Exp Pharmacol Physiol; 1988 Mar; 15(3):191-7. PubMed ID: 2978739
[TBL] [Abstract][Full Text] [Related]
10. Heart and vessel hypertrophy in hypertension: possibilities of regression.
Cífková R; Niederle P; Romanovská L; Skibová J; Frídl P; Skalická H; Widimský J
J Hypertens Suppl; 1987 Dec; 5(5):S407-10. PubMed ID: 2965227
[TBL] [Abstract][Full Text] [Related]
11. Relationship between regression of cardiovascular hypertrophy and rate of redevelopment of hypertension.
Korner PI; Jennings GL; Esler MD
J Clin Hypertens; 1987 Sep; 3(3):341-8. PubMed ID: 2959758
[No Abstract] [Full Text] [Related]
12. The future of antihypertensive treatment.
Israili ZH; Hernández-Hernández R; Valasco M
Am J Ther; 2007; 14(2):121-34. PubMed ID: 17414579
[TBL] [Abstract][Full Text] [Related]
13. Left ventricular hypertrophy and clinical outcomes in hypertensive patients.
Ruilope LM; Schmieder RE
Am J Hypertens; 2008 May; 21(5):500-8. PubMed ID: 18437140
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular structural changes and calcium antagonist therapy in patients with hypertension.
Agabiti-Rosei E; Muiesan ML; Rizzoni D; Zulli R; Calebich S; Castellano M; Cavaliere G; Nordio G; Pasini F; Zuccato F
J Cardiovasc Pharmacol; 1994; 24 Suppl A():S37-43. PubMed ID: 7603076
[TBL] [Abstract][Full Text] [Related]
15. Shifting trends in the pharmacologic treatment of hypertension in a Nigerian tertiary hospital: a real-world evaluation of the efficacy, safety, rationality and pharmaco-economics of old and newer antihypertensive drugs.
Adigun AQ; Ishola DA; Akintomide AO; Ajayi AA
J Hum Hypertens; 2003 Apr; 17(4):277-85. PubMed ID: 12714973
[TBL] [Abstract][Full Text] [Related]
16. Effects of drug therapy on hypertensive left ventricular hypertrophy.
Fletcher PJ; Horvath JS; Bailey BP; Tiller D
Clin Exp Pharmacol Physiol; 1985; 12(3):291-4. PubMed ID: 3161673
[TBL] [Abstract][Full Text] [Related]
17. Angiotensin converting enzyme inhibition and dihydropyridine calcium channel blockade in the treatment of left ventricular hypertrophy in arterial hypertension.
Palmieri V; Devereux RB
Minerva Cardioangiol; 2002 Jun; 50(3):169-74. PubMed ID: 12107398
[TBL] [Abstract][Full Text] [Related]
18. Hypertension in obesity.
Redon J
Nutr Metab Cardiovasc Dis; 2001 Oct; 11(5):344-53. PubMed ID: 11887431
[TBL] [Abstract][Full Text] [Related]
19. Left ventricular hypertrophy: how to influence an important risk factor in hypertension.
Agabiti-Rosei E; Muiesan ML
J Hypertens Suppl; 1998 Jan; 16(1):S53-8. PubMed ID: 9534098
[TBL] [Abstract][Full Text] [Related]
20. Role of cardiac and vascular amplifiers in the maintenance of hypertension and the effect of reversal of cardiovascular hypertrophy.
Korner PI; Jennings GL; Esler MD; Broughton A
Clin Exp Pharmacol Physiol; 1985; 12(3):205-9. PubMed ID: 3161672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
